Applying Emerging Evidence to Practice in Managing AMD and DME

Author(s)/Faculty: Judy E. Kim, MD; Peter A. Campochiaro, MD; Allen C. Ho, MD
Release Date: 8/13/2021Expiration Date: 8/12/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: VideoProvider:
The inclusion of anti-VEGF therapies revolutionized the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular degeneration (DME). However, data indicate that the visual gains achieved by real-world patients are suboptimal compared to those reported in clinical trials. This is primarily due to the burden of frequent injections that are require by traditional anti-VEGF therapies to ensure these outcomes. To this end, novel therapies and new drug delivery systems are under investigation to decrease treatment burden and extend the duration of action of these therapies. In this activity, expert faculty review the issues regarding the treatment burden of traditional anti-VEGF therapies and explore the emerging data supporting the use of novel therapies for nAMD and DME. They will also review the clinical data of these emerging treatment approaches and describe best practices for the various delivery routes and systems, as well as detailed discussion of surgical techniques for implantation of port delivery system with ranibizumab.